Abstract:
A method for manufacturing a potassium organotrifluoroborate derivative is provided to produce the potassium oranotrifluoroborate compound without isolation of intermediate. A method for producing a potassium organotrifluoroborate compound of the chemical formula 1 comprises: a step of reacting organic lithium reagent with a compound of the chemical formula 2 to produce a compound of the chemical formula 3; a step of reacting the compound of the chemical formual 3 with borate compound of the chemical formula 5 to produce a compound of the chemical formula 4; and a step of reacting a compound of the chemical formula 4 with potassium hydrogen fluoride to produce the compound of the chemical formula 1. In the chemical formulas 1, 2, 3, 4, and 5 are selected among phenylene, biphenylene, naphthylene, or anthrylene.
Abstract:
The present invention relates to a butenolides compound, the stereoisomers and enantiomers thereof, precursors thereof which is hydrolyzable in the body, or a pharmaceutically acceptable salt, the antimicrobial activity, preventive activity against immune diseases, effects in preventing or treating cancer, and preventive activity against fouling of a medical introducer.
Abstract:
본 발명은 하기 화학식 1로 표시되는 화합물을 유효성분으로 함유하는 염증질환 치료제에 관한 것으로, 이러한 화합물은 LPS로 활성화된 RAW 264.7세포에서 NO, IL-6 및 TNF-a와 같은 염증성 매개물의 생성을 억제함으로써 염증 질환의 치료제로서 유용하게 이용될 수 있다. [화학식 1]
Abstract:
PURPOSE: A method for a potassium organoselanyltrifluoroborate derivative is provided to prepare various potassium organoselanyltrifluoroborate derivatives containing selenium in a short reaction time without a process of refining an intermediate from a dihalogen aryl compound. CONSTITUTION: A method for a potassium organoselanyltrifluoroborate derivative comprises the steps of: preparing an organic selenium compound by mixing a dihalogen aryl compound, selenium powder and organic halogen compound, and then selectively reacting with an alkyl lithium reagent; and reacting the organic selenium compound with a trialkyl borate compound and the alkyl lithium reagent; and reacting with potassium hydrogen fluoride(KHF2).
Abstract:
PURPOSE: A therapeutic agent containing a compound as an active ingredient for treating inflammatory disease is provided to suppress generation of inflammatory media such as NO(nitrogen oxide), IL-6(interleukin-6) and TNF-α(tumor necrosis factor-alpha) in LPS-activated RAW 264.7 cell. CONSTITUTION: A therapeutic agent for treating inflammatory diseases contains a compound of the chemical formula 1 as an active ingredient. In chemical formula 1, R is COOH, COOCH3, CH2OH or CH2NHCOCF3, R1 and R2 is H, C6H5, or Br, and m is 1-5 integer and n is 1-4 integer. The compound of chemical formula 1 is (E)-11-oxooctadeca-9-enole, (E)-10- oxooctadeca-8-enole, (E)-9-oxooctadeca-10-enole or (E)-8-oxooctadeca-9-enole. The inflammatory diseases are rheumatoid arthritis, inflammatory bowel disease, osteoporosis, psoriasis, or toxic shock syndrome.
Abstract:
PURPOSE: A use of a Paecilomyces variotii extract for preventing or treating pathogenic bacterial infection in fish is provided to ensure immunity to fish diseases, and to prevent bacterial infection in fish. CONSTITUTION: A composition for preventing or treating pathogenic bacterial infection in fish contains an organic solvent extract of Paecilomyces variotii as an active ingredient. The organic solvent is selected from the group consisting of n-hexane, chloroform, ethyl acetate, and butanol. The organic solvent is ethyl acetate. The composition contains a compound denoted by chemical formula 1 as an active ingredient. A method for preventing or treating pathogenic bacterial infection in fish comprises a step of directly treating a water bath in which fish grows with the composition, or adsorbing the composition to a feed for growing fish in a concentration of 1.0-500ppm.